Literature DB >> 2429908

Immunotherapy of genital warts with inosine pranobex (Imunovir): preliminary study.

K C Mohanty, C S Scott.   

Abstract

One hundred and sixty five heterosexual men and women with genital warts were treated with inosine pranobex (Imunovir) or conventional treatment, or both. Inosine pranobex was found to be more effective in lesions of longer duration, whereas conventional treatment was more effective in genital warts of a shorter duration. Supplementation of conventional treatment with inosine pranobex increased the success rate from 41% to 94%. Immunological studies in 134 patients with genital warts showed an increased number of B cells in 21% of peripheral blood samples. Absence of major defects among circulating lymphocytes suggested that patients with genital warts may have a local immune reaction.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429908      PMCID: PMC1011990          DOI: 10.1136/sti.62.5.352

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  11 in total

1.  Wart-virus antibodies and the prognosis of wart disease.

Authors:  S Pyrhönen; K Penttinen
Journal:  Lancet       Date:  1972-12-23       Impact factor: 79.321

2.  Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer.

Authors:  D Tripodi; L C Parks; J Brugmans
Journal:  N Engl J Med       Date:  1973-08-16       Impact factor: 91.245

3.  Decreased T cell levels in patients with warts.

Authors:  J H Chretien; J G Esswein; V F Garagusi
Journal:  Arch Dermatol       Date:  1978-02

4.  Thymus derived lymphocytes (T cells) in patients with genital warts.

Authors:  K C Mohanty; R B Roy
Journal:  Br J Vener Dis       Date:  1984-06

5.  An indirect rosette technique for the identification and separation of human lymphocyte populations by monoclonal antibodies: a comparison with immunofluorescence methods.

Authors:  K Mills; R Armitage; C Worman
Journal:  Immunol Lett       Date:  1983-05       Impact factor: 3.685

6.  Regression of warts. An immunological study.

Authors:  S Pyrhönen; E Johansson
Journal:  Lancet       Date:  1975-03-15       Impact factor: 79.321

7.  Cryotherapy versus electrocautery in the treatment of genital warts.

Authors:  P D Simmons; F Langlet; R N Thin
Journal:  Br J Vener Dis       Date:  1981-08

8.  Immunophenotypes of lymphocytes in prospectively followed up human papillomavirus lesions of the cervix.

Authors:  M Väyrynen; K Syrjänen; R Mäntyjärvi; O Castrén; S Saarikoski
Journal:  Genitourin Med       Date:  1985-06

9.  Immunocompetent cells in uterine cervical lesions of human papillomavirus origin.

Authors:  K J Syrjänen
Journal:  Gynecol Obstet Invest       Date:  1983       Impact factor: 2.031

10.  Levamisole in a double-blind study: no effect on warts.

Authors:  M Schou; P Helin
Journal:  Acta Derm Venereol       Date:  1977       Impact factor: 4.437

View more
  5 in total

1.  Functional characterization of CD4 and CD8 T cell responses among human papillomavirus infected patients with ano-genital warts.

Authors:  Manjula Singh; Deepshi Thakral; Narayan Rishi; Hemanta Kumar Kar; Dipendra Kumar Mitra
Journal:  Virusdisease       Date:  2017-06-13

2.  Immunotherapy of genital warts with inosine pranobex and conventional treatment: double blind placebo controlled study.

Authors:  J Davidson-Parker; W Dinsmore; M H Khan; D A Hicks; C A Morris; D F Morris
Journal:  Genitourin Med       Date:  1988-12

Review 3.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

Review 4.  A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients.

Authors:  Stefan Miladinov Kovachev
Journal:  Infect Drug Resist       Date:  2021-06-02       Impact factor: 4.003

Review 5.  Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.

Authors:  Jiri Sliva; Chrysoula N Pantzartzi; Martin Votava
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.